<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949117</url>
  </required_header>
  <id_info>
    <org_study_id>SCUSF 0802</org_study_id>
    <secondary_id>SCUSF-0802</secondary_id>
    <secondary_id>5U10CA081920-11</secondary_id>
    <nct_id>NCT00949117</nct_id>
  </id_info>
  <brief_title>Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer</brief_title>
  <official_title>An Open Label Randomized Phase II Study of an Appetite Stimulant, Cyproheptadine Hydrochloride, With and Without a Nutritional Supplement, in Children With Cancer/Treatment-Related Weight Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Cyproheptadine hydrochloride may help improve appetite and lessen weight loss
      caused by cancer or cancer treatment. It is not yet known whether cyproheptadine
      hydrochloride is more effective with or without nutritional supplementation in improving
      weight and quality of life of young patients with weight loss caused by cancer or cancer
      treatment.

      PURPOSE: This randomized phase II trial is studying cyproheptadine hydrochloride to see how
      well it works when given together with or without nutritional supplementation in treating
      young patients with weight loss caused by cancer or cancer treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare the efficacy of an appetite stimulant, cyproheptadine hydrochloride, with vs
           without a nutritional supplement, PediaSure or Ensure, in improving weight and extending
           the duration of response in pediatric patients with cancer- or cancer treatment-related
           weight loss.

      Secondary

        -  To compare patterns of body composition and weight change in patients treated with these
           regimens.

        -  To compare the change in the relationship between pre-albumin (biomarker of
           malnutrition) and weight improvement from baseline to the completion of study treatment.

        -  To compare the change in quality of life as measured by the Pediatric Functional
           Assessment of Anorexia and Cachexia Therapy (FAACT) questionnaire in patients treated
           with these regimens.

      OUTLINE: This is a multicenter study. Patients are stratified according to participating
      center and steroid use (yes vs no). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks
           in the absence of weight loss or unacceptable toxicity.

        -  Arm II: Patients receive oral cyproheptadine hydrochloride twice daily and oral
           PediaSure (2 to 10 years of age) or Ensure (&gt; 10 years of age) twice daily for up to 24
           weeks in the absence of weight loss or unacceptable toxicity.

      Patients undergo blood sample collection to assess pre-albumin levels at baseline and at
      weeks 4 and 24. Patients also undergo assessment of body composition, lean body mass, and
      percentage of body fat at baseline and at weeks 4 and 24 and assessment of weight and height
      at baseline and at weeks 4, 8, 12, 16, 20, and 24. Patients also complete a food diary twice
      a week during study treatment.

      Patients 7-17 years of age complete a quality-of-life questionnaire at baseline and at weeks
      4 and 24.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study not feasible with low accrual. DSMB recommended closure
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference Between Measures of Weight at Baseline and at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Difference in measure of weight in kilograms of subject at baseline and at week 24 after continuing on study treatment for the entire 24 week period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index as Assessed at Baseline and 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Body Mass Index (BMI) in subjects from Baseline visit to 24 week visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Cyproheptadine Hydrochloride on Pre-albumin and Body Composition</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Assessed by Peds-FAACT Questionnaire at Baseline and at Weeks 4 and 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight for Age Z-score From Baseline Through 24 Weeks</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change in weight for age Z-score from Baseline through 24 weeks while on study treatment. Weight for age Z-score calculated using the Center for Disease Control and Prevention (CDC) weight-for-age Z score data tables.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Malnutrition</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <condition>Weight Changes</condition>
  <arm_group>
    <arm_group_label>Arm I- cyproheptadine hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cyproheptadine HCl &amp; PediaSure or Ensure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (&gt; 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ensure</intervention_name>
    <description>Given orally</description>
    <arm_group_label>cyproheptadine HCl &amp; PediaSure or Ensure</arm_group_label>
    <other_name>nutritional supplement drink</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PediaSure</intervention_name>
    <description>Given orally</description>
    <arm_group_label>cyproheptadine HCl &amp; PediaSure or Ensure</arm_group_label>
    <other_name>nutritional supplement drink (pediatric)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyproheptadine hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I- cyproheptadine hydrochloride</arm_group_label>
    <arm_group_label>cyproheptadine HCl &amp; PediaSure or Ensure</arm_group_label>
    <other_name>cyproheptadine HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  â‰¥ 2 years and &lt; 18 years of age at the time of admission to the study

          -  Meets one of the following criteria:

          -  documented history of unintended weight loss &gt; 5% presumed secondary to
             cancer/treatment-related therapy within three months

          -  BMI for age less than the 5th percentile

          -  Diagnosed with cancer of any type

          -  Concomitant cancer treatment (surgery, chemotherapy, radiotherapy) guidelines:

          -  Patients who will complete concomitant cancer treatment during this study's 4-week
             intervention are not eligible

          -  If patients are receiving concomitant cancer treatment, they should be scheduled to
             get at least another 4 weeks of treatment in order to reach the primary endpoint

          -  If patients have already completed cancer treatment, they need to be enrolled within 8
             weeks of completing therapy.

          -  Predicted life expectancy of at least 6 months

        EXCLUSION CRITERIA:

          -  Currently taking any of the study agents (cyproheptadine hydrochloride (CH),
             PediaSure, or Ensure) or have taken any of the study agents during the past 3 weeks

          -  History of anorexia nervosa or bulimia

          -  Initiation of other appetite enhancing agents including steroids prescribed for the
             intent of weight gain, i.e. Megace, is not allowed during this study

          -  Children receiving steroids as part of their daily cancer treatment regimen are
             excluded from participation. However, intermittent steroid use in an antiemetic
             regimen or in other pulse steroid therapy is allowed during the study.

          -  Use of other forms of nutrition therapies, e.g. total parenteral nutrition (TPN) or
             enteral tube feedings within 3 weeks of study entry or during study

          -  Receiving monoamine oxidase (MAO) inhibitors, procarbazine, fluoxetine (SSRI), or
             paroxetine (SSRI)

          -  Taking dronabinol (Marinol) or other appetite-stimulating medications during the past
             3 weeks

          -  Diagnosed with glaucoma, cystic fibrosis, inflammatory bowel disease or GI or
             genitourinary (GU) obstruction

          -  Allergy to study agents

          -  Hypersensitivity to specific milk proteins

          -  Pregnant or lactating. Females of childbearing potential are required to use effective
             contraception while on study agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marisa Couluris, DO</last_name>
    <role>Study Chair</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <results_first_submitted>July 8, 2013</results_first_submitted>
  <results_first_submitted_qc>January 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2014</results_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malnutrition</keyword>
  <keyword>weight changes</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia</keyword>
  <keyword>other myeloid malignancies</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage I childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage II childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage III childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage I childhood large cell lymphoma</keyword>
  <keyword>stage II childhood large cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage I childhood lymphoblastic lymphoma</keyword>
  <keyword>stage II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>childhood Burkitt lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage I childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Body Weight Changes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproheptadine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I- Cyproheptadine Hydrochloride</title>
          <description>Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Arm II Cyproheptadine HCl and PediaSure or Ensure</title>
          <description>Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (&gt; 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I- Cyproheptadine Hydrochloride</title>
          <description>Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Arm II Cyproheptadine HCl and PediaSure or Ensure</title>
          <description>Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (&gt; 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.1" spread="5.5"/>
                    <measurement group_id="B2" value="13.3" spread="5.1"/>
                    <measurement group_id="B3" value="11.4" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference Between Measures of Weight at Baseline and at Week 24</title>
        <description>Difference in measure of weight in kilograms of subject at baseline and at week 24 after continuing on study treatment for the entire 24 week period.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I- Cyproheptadine Hydrochloride</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm II Cyproheptadine HCl and PediaSure or Ensure</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (&gt; 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Measures of Weight at Baseline and at Week 24</title>
          <description>Difference in measure of weight in kilograms of subject at baseline and at week 24 after continuing on study treatment for the entire 24 week period.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index as Assessed at Baseline and 24 Weeks</title>
        <description>Change in Body Mass Index (BMI) in subjects from Baseline visit to 24 week visit.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I- Cyproheptadine Hydrochloride</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm II Cyproheptadine HCl and PediaSure or Ensure</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (&gt; 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index as Assessed at Baseline and 24 Weeks</title>
          <description>Change in Body Mass Index (BMI) in subjects from Baseline visit to 24 week visit.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Cyproheptadine Hydrochloride on Pre-albumin and Body Composition</title>
        <time_frame>24 weeks</time_frame>
        <population>Outcome not assessed as the one subject that completed the protocol did not have the prealbumin lab drawn at the 24 week visit and body composition tests assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I- Cyproheptadine Hydrochloride</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm II Cyproheptadine HCl and PediaSure or Ensure</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (&gt; 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Cyproheptadine Hydrochloride on Pre-albumin and Body Composition</title>
          <population>Outcome not assessed as the one subject that completed the protocol did not have the prealbumin lab drawn at the 24 week visit and body composition tests assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Assessed by Peds-FAACT Questionnaire at Baseline and at Weeks 4 and 24</title>
        <time_frame>24 weeks</time_frame>
        <population>Outcome not assessed as the one subject that completed the protocol was too young to complete the PedsFAACT quality of life assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I- Cyproheptadine Hydrochloride</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm II Cyproheptadine HCl and PediaSure or Ensure</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (&gt; 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Assessed by Peds-FAACT Questionnaire at Baseline and at Weeks 4 and 24</title>
          <population>Outcome not assessed as the one subject that completed the protocol was too young to complete the PedsFAACT quality of life assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight for Age Z-score From Baseline Through 24 Weeks</title>
        <description>Change in weight for age Z-score from Baseline through 24 weeks while on study treatment. Weight for age Z-score calculated using the Center for Disease Control and Prevention (CDC) weight-for-age Z score data tables.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I- Cyproheptadine Hydrochloride</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
cyproheptadine hydrochloride: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Cyproheptadine HCl &amp; PediaSure or Ensure</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (&gt; 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
Ensure: Given orally
PediaSure: Given orally
cyproheptadine hydrochloride: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight for Age Z-score From Baseline Through 24 Weeks</title>
          <description>Change in weight for age Z-score from Baseline through 24 weeks while on study treatment. Weight for age Z-score calculated using the Center for Disease Control and Prevention (CDC) weight-for-age Z score data tables.</description>
          <units>z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <desc>Subjects and their parents reported any adverse symptoms or events via daily study medication logs. Site personnel reviewed logs at in-person visits at weeks 4, 8, 12, 16, 20 and 24 and assessed subject for any adverse events. All Adverse events and Serious Adverse events reviewed by independent DSMB.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I- Cyproheptadine Hydrochloride</title>
          <description>Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Arm II Cyproheptadine HCl and PediaSure or Ensure</title>
          <description>Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (&gt; 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>relapse of cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study closed early due to slow accrual and lack of feasibility Only 1 subject completed protocol and considered in the outcome measures. Subject too young to complete PedsFAACT &amp; did not have prealbumin drawn at 24 week visit so outcomes not assessed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cristina Burroughs, Clinical Research Coordinator</name_or_title>
      <organization>SunCoast CCOP Research Base</organization>
      <phone>(813) 396-9237</phone>
      <email>Cristina.Burroughs@epi.usf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

